国家引进新疫苗的决策机制:2010-2020年系统综述
该系统综述检索2010年3月至2020年8月六个数据库中有关疫苗引进 policymaking 的文献,最终纳入116篇。常见决策标准包括疾病负担、疫苗效力/效果与安全性、健康与非健康结局影响、经济评价与成本效果;程序性与可接受性方面较少被考虑。多数描述引进决策过程的文章强调国家、区域或全球循证建议及稳健的国家治理是促进疫苗采纳的因素。
要点
- 决策标准以疾病负担、疫苗效力/效果与安全性、经济评价与成本效果为主。
- 程序性与可接受性方面在决策标准中较少被考虑。
- 国家、区域或全球循证建议及稳健国家治理是疫苗采纳的促进因素。
核心结论
- 自2010年以来疫苗采纳决策文献有所扩展,决策者与专家咨询委员会成员(如国家免疫技术咨询组NITAG)日益重视基于经济评价的干预措施。
研究设计与样本
- 系统综述,检索2010年3月至2020年8月六个数据库,筛查3808条唯一参考文献,最终纳入116篇符合标准的文献。
主要发现
- 116篇文献分类为:疫苗采纳决策框架27篇、分析疫苗采纳决策实证数据或案例的研究45篇、提供疫苗 policymaking 过程见解的理论与实证文章44篇(另17篇已纳入前两类)。
- 常见决策标准包括疾病负担、疫苗效力/效果与安全性、对健康与非健康结局的影响、经济评价与替代干预措施的成本效果。
- 程序性与可接受性方面较少被考虑。
- 61篇描述疫苗引进 policymaking 过程的文章中,50篇(82%)强调国家、区域或全球循证建议及稳健的国家治理是疫苗采纳的促进因素。
关键数值与推荐
- 常见决策标准:疾病负担;疫苗效力/效果与安全性;对健康与非健康结局的影响;经济评价与替代干预措施的成本效果。
临床怎么用
- 可为国家级、次区域和区域利益相关方讨论循证免疫决策提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Competing priorities make using a transparent and evidence-based approach important when deciding to recommend new vaccines. We conducted a literature review to document the processes and frameworks for national decision-making on new vaccine introductions and explored which key features have evolved since 2010. METHODS: We searched literature published on policymaking related to vaccine introduction from March 2010 to August 2020 in six databases. We screened articles for eligibility with the following exclusion criteria: non-human or hypothetical vaccines, the sole focus on economic evaluation or decision to adopt rather than policy decision-making. We employed nine broad categories of criteria from the 2012 review for categorization and abstracted data on the country, income level, vaccine, and other relevant criteria. RESULTS: Of the 3808 unique references screened, 116 met eligibility criteria and were classified as: a) framework of vaccine adoption decision-making (27), b) studies that analyse empirical data on or examples of vaccine adoption decision-making (45), c) theoretical and empirical articles that provide insights into the vaccine policymaking process (44 + 17 already included in the previous categories). Commonly reported criteria for decision-making were the burden of disease; vaccine efficacy/effectiveness, safety; impact on health and non-health outcomes; economic evaluation and cost-effectiveness of alternative interventions. Programmatic and acceptability aspects were not as often considered. Most (50; 82%) of the 61 articles describing the process of vaccine introduction policymaking highlighted the role of country, regional, or global evidence-informed recommendations and a robust national governance as enabling factors for vaccine adoption. CONCLUSIONS: The literature on vaccine adoption decision-making has expanded since 2010. We found that policymakers and expert advisory committee members (e.g., National Immunization Technical Advisory Group [NITAG]) increasingly value the interventions based on economic evaluations. The results of this review could guide discussions on evidence-informed immunization decision-making among country, sub-regional, and regional stakeholders.
引用
- Donadel M, Panero MS, Ametewee L, et al. National decision-making for the introduction of new vaccines: A systematic review, 2010-2020. Vaccine. 2021. PMID: 33750592. doi:10.1016/j.vaccine.2021.02.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。